Can charcoal improve outcomes in COVID-19 infections?

Abstract

COVID-19 infection causes considerable morbidity and mortality, especially to those who are aged, have impaired renal function and are obese. We propose to examine the potential utility of oral activated charcoal with the hypothesis that such treatment would lower absorption of microbiome derived toxins and ameliorate systemic oxidant stress and inflammation.

• Authors: Zeid J Khitan, Imran Khawaja, Maurice A Mufson, Juan R Sanabria, Nader G Abraham, Stephen J Peterson, Uma Sundaram, Joseph I Shapiro
• Journal: Medical hypotheses (Med Hypotheses) Vol. 144 Pg. 110176 (Nov 2020) ISSN: 1532-2777 [Electronic] United States
• PMID: 33254498 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Chemical References

• Antiviral Agents
• Cytokines
• Oxidants
• Charcoal

Topics

• Adipocytes (cytology, metabolism)
• Antiviral Agents (therapeutic use)
• COVID-19 (microbiology, therapy)
• Charcoal (pharmacology)
• Cytokines (metabolism)
• Gastrointestinal Microbiome
• Humans
• Inflammation
• Kidney Diseases (complications)
• Models, Theoretical
• Obesity (complications)
• Oxidants (metabolism)
• Oxidative Stress
• Risk